|Dr. Brian S. Murphy||CEO, Chief Medical Officer & Director||253.85k||N/A||1958|
|Dr. Avtar S. Dhillon||Exec. Chairman & Chairman of Advisory Board||N/A||N/A||1961|
|Mr. Douglas A. Cesario||Chief Financial Officer||N/A||N/A||1975|
|Ms. Wendy Cunning||VP of Bus. Operations||N/A||N/A||N/A|
Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.
Nemus Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.